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Significance of this study
What is already known on this subject?
 ► An increase in the incidence of colorectal 
cancer (CRC) among subjects aged 20–40 years 
has been observed in North America, Australia 
and China.
 ► The American Cancer Society therefore recently 
recommended to lower the age to start 
screening from 50 to 45 years.
What are the new findings?
 ► The incidence of CRC increases in Europe 
among subjects aged 20–49 years.
 ► The fastest rise in incidence occurs in the 
youngest age group.
 ► The rise in incidence was more prominent for 
colon cancer than for rectal cancer.
 ► The rise in incidence is not associated with a 
similar rise in mortality.
How might it impact on clinical practice in the 
foreseeable future?
 ► The increasing incidence of CRC among 
younger subjects asks for reconsideration of 
screening guidelines.
 ► A continued increase in incidence will require 
to lower the age to start screening.
 ► Further research is needed to identify 
underlying aetiological factors.
 ► Clinicians should be aware of the rising 
incidence of CRC in young adults.
AbSTrACT
Objective the incidence of colorectal cancer (crc) 
declines among subjects aged 50 years and above. an 
opposite trend appears among younger adults. in europe, 
data on crc incidence among younger adults are 
lacking. We therefore aimed to analyse european trends 
in crc incidence and mortality in subjects younger than 
50 years.
Design Data on age-related crc incidence and 
mortality between 1990 and 2016 were retrieved from 
national and regional cancer registries. trends were 
analysed by Joinpoint regression and expressed as 
annual percent change.
results We retrieved data on 143.7 million people 
aged 20–49 years from 20 european countries. Of 
them, 187 918 (0.13%) were diagnosed with crc. On 
average, crc incidence increased with 7.9% per year 
among subjects aged 20–29 years from 2004 to 2016. 
the increase in the age group of 30–39 years was 4.9% 
per year from 2005 to 2016, the increase in the age 
group of 40–49 years was 1.6% per year from 2004 
to 2016. this increase started earliest in subjects aged 
20–29 years, and 10–20 years later in those aged 30–39 
and 40–49 years. this is consistent with an age-cohort 
phenomenon. although in most european countries the 
crc incidence had risen, some heterogeneity was found 
between countries. crc mortality did not significantly 
change among the youngest adults, but decreased with 
1.1%per year between 1990 and 2016 and 2.4% per 
year between 1990 and 2009 among those aged 30–39 
years and 40–49 years, respectively.
Conclusion crc incidence rises among young 
adults in europe. the cause for this trend needs to be 
elucidated. clinicians should be aware of this trend. if 
the trend continues, screening guidelines may need to be 
reconsidered.
InTrODuCTIOn
The overall crude incidence of colorectal cancer 
(CRC) increased in most European countries over the 
last decade. The annual increase ranged in different 
countries between 0.4% and 3.6%.1 The recent intro-
duction of CRC screening in most European coun-
tries will likely reverse this trend.2 3 These screening 
programmes typically target subjects aged 50 years 
and above. In several parts of the world, the CRC 
incidence has also risen in individuals below 50 years 
of age. In the USA, the incidence of colon cancer 
increased since 1974 with 1.0%–2.4% annually and 
the incidence of rectal cancer with 3.2%.4 
The possible reasons for this increasing incidence 
are unknown, but may be related to the increasing 
prevalence of obesity, lack of exercise and to dietary 
factors such as alcohol and processed meat.3 Further-
more, urbanisation and pollution have been impli-
cated in the overall increase in cancer incidence.5 
CRC in young adults is in part due to hereditary 
cancer syndromes, but most cases are sporadic.6
The changing epidemiology of CRC may also 
have practical implications, in particular for age to 
start screening. With the use of the Microsimulation 
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showed that screening initiation at age 45 years had in the US 
population a favourable balance between screening benefits and 
burdens.7 This finding supported the American Cancer Society 
to recommend starting screening at age 45 years instead of 50 
years.8
Whether the incidence of CRC also increases among young 
adults in Europe has not been investigated. We therefore anal-
ysed trends in CRC incidence in this population.
MeTHODS
Study design and data source
Data on age-specific incidence and mortality of CRC by year 
of diagnosis were retrieved from national and regional Euro-
pean cancer registries with a time frame of at least 10 years 
(online supplementary table 1). We evaluated incidence and 
mortality of CRC, colon cancer (ICD-O-3 codes C18) and rectal 
cancer (C20) between 1990 and 2016. Data were collected for 
subjects aged 20–49 years. Five-year incidence and mortality 
rates were collected and expressed per 100 000 persons.
Statistical analysis
Temporal trends in CRC incidence within the study period were 
investigated using Joinpoint regression analyses, applying an 
algorithm to define significant changes in temporal trends on a 
logarithmic scale. The annual percent change (APC) in each Join-
point segment represents the rate of change in cancer incidence 
per year in a given time period. The analyses were performed 
using the Joinpoint Regression Programme 4.5.0.1, National 
Cancer Institute.
All tests of statistical significance were two-sided; a p value 
of <0.05 was considered significant. Incidence rates were 
calculated for three age groups (20–29, 30–39, 40–49 years), 
presented per 100 000 persons and adjusted to population 
numbers for each country.
As not all countries could provide data over the entire time 
period, a sensitivity analysis was performed with data from 
countries that covered the entire time frame.
We set out to distinguish between a period effect and a cohort 
effect. While a period effect results from external factors that 
equally affect all age groups at a particular time period, a cohort 
effect represents variations resulting from unique exposure of 
a specific birth cohort. To this aim, we identified for each age 
group the year in which the increase in CRC incidence, if any, 
had started. If it were to be the same for the three age groups, 
the increase in incidence was considered to be a period effect. If 
the starting year were to be more recent in the older age groups, 
the increase was considered to be a cohort effect.
reSulTS
Incidence data were available from 20 European countries 
(figure 1); mortality data from 16 of those (not including 
Belgium, France, the UK and Ireland). In 2009, the population 
of these 20 countries numbered 91 842 346 individuals aged 
20–39 years, of whom 47 364 were diagnosed with CRC from 
1990 to 2016, and 51 868 457 individuals aged 40–49 years, of 
whom 140 554 were diagnosed with CRC from 1990 to 2016.
Incidence of colorectal cancer
Age group 20–29 years
For both sexes combined, CRC incidence increased from 0.8 
to 2.3 cases per 100 000 persons between 1990 and 2016. 
This increase was 1.7% per year between 1990 and 2004, and 
then rose to 7.9% increase per year between 2004 and 2016 
(figure 2). In men, the CRC incidence increased with 2.6% per 
year between 1992 and 2005. This increase rose to 7.4% per 
year between 2005 and 2016. In women, the CRC incidence 
increased with 1.8% per year between 1990 and 2003 and with 
8.1% per year between 2003 and 2016. The incidence of colon 
cancer rose more markedly (2.7% per year between 1990 and 
2005 and 9.3% per year between 2005 and 2016) than the inci-
dence of rectal cancer. The latter increased with 3.5% annually 
throughout the whole period without an acceleration over time.
Age group 30–39 years
For both sexes combined, in age group 30–39 years the CRC 
incidence increased, although less steeply than in age group 
20–29 years (figure 2). In men, the CRC incidence increased 
with 3.4% per year between 2001 and 2016 (from 3.7 to 7.1 
cases per 100 000 persons between 1990 and 2016). In women, 
no significant change in trend was observed between 1990 and 
2005, but the CRC incidence increased with 6.8% annually 
between 2005 and 2016 (from 2.8 to 6.4 cases per 100 000 
persons between 2006 and 2016). The colon cancer incidence 
increased between 2006 and 2016 with 6.4% per year; that of 
rectal cancer with 1.6% per year between 1990 and 2016.
Age group 40–49 years
In age group 40–49 years, the CRC incidence decreased with 
0.8% between 1990 and 2004, but increased with 1.6% per year 
between 2004 and 2016 (incidence increased from 15.5 to 19.2 
cases per 100 000 persons between 2005 and 2016). The same 
trend was observed for colon cancer: the incidence decreased 
with 1.3% per year between 1990 and 2004 and then increased 
with 1.6% annually between 2004 and 2016. No significant 
change in trend was observed for rectal cancer (figure 2).
Country-specific trends
Trends in incidence of CRC per European region are shown in 
figure 1. CRC incidence increased significantly among subjects 
aged 20–39 years in 12 countries: Belgium, Germany, the Neth-
erlands, the UK, Norway, Sweden, Finland, Ireland, France, 
Denmark, Czech Republic and Poland. Italy showed a decrease in 
incidence in this age group. No significant change was observed 
in the remaining six countries (online supplementary figure 1).
CRC incidence increased significantly among subjects aged 
40–49 years in eight countries: the UK, Greenland, Sweden, 
Slovenia, Germany, Finland, Denmark and the Netherlands. 
Only Czech Republic showed a significant decrease in incidence 
from 1997 to 2015. No significant change was observed in the 
remaining 11 countries (online supplementary figure 2).
Sensitivity analyses
Not all countries could provide data over the entire time period 
of 1990 to 2016. We therefore performed sensitivity analyses for 
the longest possible time frame: 1991 to 2014. Data from nine 
countries were included: Denmark, Finland, Norway, Sweden, 
the Netherlands, Greenland, Slovenia, Czech Republic and Swit-
zerland. The outcomes indicated increases in the incidence of 
both colon and rectal cancer in all age groups (figure 3).
Period or cohort effect
We assessed by means of sensitivity analysis whether the increase 
in incidence was a period or a cohort effect (figure 3). This 
showed that adults aged 20–29 years had an increase in CRC 
incidence from 1991 to 2014. In age group 30–39 years, a rise in 
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Figure 1 Annual percent change (APC) in colorectal cancer (CRC) incidence from the European countries included in the analysis in adults aged 
20–39 years, 1990–2016. Light green to dark green: significant increase in CRC incidence rate; blue: significant decrease in CRC incidence rate; grey: 
no significant trend.
in incidence was observed among those aged 40–49 years. This 
difference in starting points is compatible with a cohort effect.
Mortality due to colorectal cancer
Age group 20–39 years
The mortality rate for CRC did not significantly change in 
the age group 20–29 years. In the age group 30–39 years, the 
mortality decreased with 1.1% per year (figure 4). The mortality 
rate of colon cancer decreased with 9.7% per year between 1990 
and 1993, and with 0.5% per year between 1993 and 2014, to 
remained stable from 2014 onwards. No significant change in 
mortality was observed for rectal cancer.
Age group 40–49 years
The overall mortality of CRC in the age group 40–49 years 
decreased with 2.4% per year between 1990 and 2009, but 
increased with 1.1% per year between 2009 and 2016 (figure 4). 
The mortality rate of colon cancer decreased with 2.4% per year 
between 1990 and 2010, and remained stable between 2010 and 
2016. The mortality rate of rectal cancer decreased with 2.6% 
per year between 1990 and 2006, and remained stable between 
2006 and 2016.
DISCuSSIOn
Our study showed an increase in CRC incidence in adults aged 
20–49 years in Europe. The largest increase in CRC incidence 
occurred among subjects aged 20–39 years. The incidence of colon 
cancer increased with 6.4%–9.3% annually; that of rectal cancer 
with 1.6%–3.5% per year. The causes of this increase are yet 
unknown. Awareness of this trend is relevant to identify patients at 
risk. Further research is needed to determine whether the trend can 
be reversed, among others by lowering the age to start screening.
In the past years, an increase in CRC incidence in young adults 
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Figure 2 Annual percent change (APC) in age-specific colorectal cancer (CRC), colon cancer and rectal cancer incidence rates in Europe, 1990–2016. 
*Indicates that APC is statistically significant different from zero.
USA.4 In Canadian subjects aged 20–29 years, the incidence of 
colon cancer rose faster than that of rectal cancer (APC 6.2%, 
respectively 1.5%). CRC incidence in young adults also rises in 
Australia and China. In the latter country, adoption of a Western 
lifestyle is thought to contribute to this trend.9 10
In the USA, the increase in CRC incidence was explained by 
a cohort effect. Our data support a similar effect in Europe. 
The incidence started to rise exactly 10 years earlier in the age 
groups 30–39 years than in the group of 40–49 years. CRC inci-
dence also rose among those aged 20–29 years, however, with 
no turning point during the study period. This suggests that the 
turning point already occurred before 1990.
The cause of this trend is unknown. A combination of factors 
is likely to have contributed. This includes the increasing prev-
alence of obesity. The latter parallels the increase in CRC inci-
dence in young adults.11 A meta-analysis showed that weight 
gain is associated with an increased risk of CRC.12 Excess nutri-
ents may initiate a chronic low-grade inflammatory response in 
metabolic cells.13 Also, other risk factors such as lack of physical 
activity, increased alcohol intake and cigarette smoking may play 
a role.14–17
We found that the rate of increase differed for colon and 
rectal cancer, ranging from 1.6% to 9.3% for colon cancer vs 
0% to 3.5% for rectal cancer. Although the above-mentioned 
risk factors apply to both colon and rectal cancer, some factors 
are strongly associated with colon cancer only. Lifestyle factors 
such as diet, physical activity and alcohol have been associated 
with risk of colon cancer, but not with rectal cancer.18 Also, a 
meta-analysis showed that obesity was in particular associated 
with an increased risk of colon cancer. For rectal cancer this asso-
ciation was less apparent in men, and absent in women.19 This 
might in part be explained by the greater susceptibility of the 
colon to the effects of insulin in comparison with the rectum.20
The increasing use of colonoscopy for diagnostic and 
screening purposes may have been responsible for a propor-
tion of the detected CRCs in young adults. Nevertheless, detec-
tion bias is probably not the driving factor for this trend, since 
young adults are less likely to be screened for CRC, the rise was 
most marked in the youngest age group and the turning points 
differed between age groups.
Current guidelines in Europe recommend CRC screening from 
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Figure 3 Annual percent change (APC) in age-specific colorectal cancer (CRC), colon cancer and rectal cancer incidence rates in nine European 
countries, 1991–2014. Analyses on trend in incidence of CRC was based on nine countries: Slovenia, Norway, Denmark, Sweden, Finland, the 
Netherlands, Czech Republic, Switzerland and Greenland. Analyses on trend of incidence of colon cancer and rectum cancer was based on eight 
countries: Slovenia, Norway, Denmark, Sweden, Finland, the Netherlands, Czech Republic and Greenland. *Indicates that APC is statistically significant 
different from zero.
to start screening at the age of 45. This recommendation was 
based on the burden of disease, the increasing incidence among 
younger subjects, the results of modelling and the assumption that 
screening the age group 45–49 years will have preventive effect 
as screening those 50 years and above. The American Cancer 
Society’s analyses showed a favourable benefit-to-burden balance 
with an expected reduction in CRC mortality and incidence.8 For 
several reasons, the results of our study provide no argument for 
starting screening at the age of 45 years in Europe. First, the largest 
increase in CRC incidence rate was observed in the age group of 
20–39 years. Second, the rate of change in CRC incidence differed 
between countries. Third, the absolute numbers of CRC in these 
age groups still remain low in comparison with elderly subjects. 
Fourth, most European countries struggle to find the resources to 
properly screen the age group of 50–75 years, or are in the process 
of implementing screening for this group. For these reasons, it is 
too early to use our data to support screening for those aged 45–50 
years. However, it is relevant to research to monitor this trend, and 
repeatedly assess whether screening practice needs to be adapted. 
Furthermore, we should find underlying causes, and identify high-
risk subjects who might benefit from earlier screening. A first step 
to reach this goal is to make clinicians aware that the CRC inci-
dence in young adults is rising quite rapidly.
Italy is the only country that showed a significant decrease in 
CRC incidence among subjects aged 20–39 years. This occurred 
at a rate of 1.8% per year from 1998 onwards. We should be 
careful with data interpretation though, because the observation 
might be due to selection bias. The Italian data were retrieved 
from the AITRUM database, covering only nine regions from 
1996 to 2009 instead of the entire country over a longer period.
The incidence trend did not significantly change in Green-
land, Iceland, Slovenia, Catalonia, Latvia and Switzerland. 
This can likely be explained by the low population numbers in 
these countries, affecting power of our calculations.
This study is the first to give an overview of CRC incidence 
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Figure 4 Annual percent change (APC) in age-specific colorectal cancer (CRC), colon cancer and rectal cancer mortality rates in Europe, 1990–2016. 
*Indicates that APC is statistically significant different from zero.
is the use of data from 20 European counties. Still, several limita-
tions need to be addressed. First, not all European Union member 
countries could be included, either because of the lack of a national 
cancer registry or inaccessibility of the data. Also, for some countries 
(Portugal, Spain and Italy), data were only available for only a limited 
number of regions. Second, not all countries could provide data 
over a period of 25 years, because some national cancer registries 
were set up in a later year. In all countries, however, data were avail-
able for at least 10 years. The analysis of data from countries with 
a longer observation period (1991–2014) consistently showed the 
same trends. Third, the quality of data differed between countries. 
Data quality was estimated in terms of microscopically verified (MV) 
and death certificate only (DCO). The German data, for example, 
had an MV rate of 85.6% and a DCO rate of 13%. The Latvian 
data had an MV rate of 80.7% and a DCO rate of 5.5%. Fourth, 
the national cancer registries from Switzerland and Germany present 
estimated nationwide data on CRC incidence, because not all regions 
can provide CRC incidence and mortality rates. Fifth, individual data 
were not accessible. It was not possible, therefore, to differentiate 
between left and right colon cancers and pathological characteristics 
of patients with CRC could not be retrieved.
In conclusion, the incidence of CRC is rising in Europe among 
subjects aged 20–49 years. If this trend continues, screening 
guidelines may need to be reconsidered. Until the underlying 
cause of this trend is clarified, it would be commendable to 
raise clinicians’ awareness and identify factors possibly associ-
ated with this trend.
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